5,6-Methylenedioxy-2-aminoindane (MDAI) has become a common substitute for (± )-3,4-methylenedioxymethamphetamine (MDMA) in Ecstasy. MDAI is known to produce MDMA-like discriminative stimulus effects, but it is not known whether MDAI has psychostimulant or hallucinogen-like effects. MDAI was tested for locomotor stimulant effects in mice and subsequently for discriminative stimulus effects in rats trained to discriminate cocaine (10 mg/kg, intraperitoneally), methamphetamine (1 mg/kg, intraperitoneally), ± MDMA (1.5 mg/kg, intraperitoneally), or (− )-2,5-dimethoxy-4-methylamphetamine hydrochloride (0.5 mg/kg, intraperitoneally) from saline. The ability of MDAI to produce conditioned place preference was also tested in mice. MDAI (3 to 30 mg/kg) depressed locomotor activity from 10 to 60 min. A rebound stimulant effect was observed at 1 to 3.5 h following 30 mg/kg. Lethality occurred in 8/8 mice following 100 mg/kg MDAI. Similarly, MDMA depressed locomotor activity immediately following the administration of 0.25 mg/kg and stimulant effects were observed 50-70 min following the administration of 0.5 and 1 mg/kg. MDAI fully substituted for the discriminative stimulus effects of MDMA (2.5 mg/kg), (− )-2,5-dimethoxy-4-methylamphetamine hydrochloride (5 mg/kg), and cocaine (7.5 mg/kg), but produced only 73% methamphetamine-appropriate responding at a dose that suppressed responding (7.5 mg/kg). MDAI produced tremors at 10 mg/kg in one methamphetamine-trained rat. MDAI produced conditioned place preference from 0.3 to 10 mg/kg. The effects of MDAI on locomotor activity and drug discrimination were similar to those produced by MDMA, having both psychostimulant-like and hallucinogenlike effects; thus, MDAI may have similar abuse potential as MDMA.
Introduction 5,6-Methylenedioxy-2-aminoindane (MDAI), which has a structure similar to 3,4-methylenedioxymethamphetamine (MDMA), has become a popular club drug (Sainsbury et al., 2011; Corkery et al., 2013) . Typically, clubs drugs such as MDMA and MDAI are taken for their social-enhancing effects rather than for any psychostimulant effects, and are reported by users to induce feelings of empathy, closeness to others, relaxation, and happiness (Cohen, 1995) . Other compounds are reported to produce similar effects, and these drugs have been labeled entactogens on the basis of their distinctive subjective effects. MDMA is a common component of the club drugs called Ecstasy, Mandy, or Molly, which are used largely during 'raves' (i.e. large dance parties) to increase energy and social interaction (Kalant, 2001) . Use of club drugs including MDMA has been increasing steadily (Parrot and Lasky, 1998; Scholeya et al., 2004; Winstock et al., 2012) . However, whereas MDMA is a controlled substance in the USA and elsewhere, MDAI is not controlled (Casale and Hays, 2011) . Because of its similarity to both stimulants and hallucinogens, MDMA produces a unique profile of abuse liability, wherein compulsive use is limited relative to classical psychostimulants such as cocaine and methamphetamine, but dependence and withdrawal have been self-reported in a small subset of users (Cottler et al., 2009; Degenhardt et al., 2010) .
MDMA produces a wide range of effects on several neurotransmitter systems, including blockade of dopamine, serotonin, and norepinephrine transporters, and release of monoamines, and it also acts as an agonist at 5-HT1A and 5-HT2A receptors [see reviews by Cole and Sumnall (2003) ; Schenk (2011)] . Similarly, MDAI causes the release of 5-HT (Johnson et al., 1991b) , but also inhibits uptake of dopamine, norepinephrine, and serotonin to a lesser extent (Johnson et al., 1991a) .
Because the discriminative stimulus effects of MDMA are both serotonin and dopamine mediated, it is not surprising that MDMA produces effects similar to both hallucinogens and psychostimulants. MDMA produces some psychostimulant-like effects and some hallucinogen-like effects. It fully cross-substitutes with methamphetamine (i.e. MDMA fully substitutes in methamphetamine-trained rats and methamphetamine fully substitutes in MDMA-trained rats), but shows inconsistent cross-substitution with cocaine and amphetamine [see review in Gatch et al. (2009) ]. In contrast, MDMA fully substituted in rats trained to discriminate 2,5-dimethoxy-4-methylamphetamine hydrochloride (DOM) and DMT, and partially substituted in lysergic acid diethylamide (LSD)-trained rats, whereas LSD produced full substitution in MDMA-trained rats, and DOM and DMT only partially substituted for MDMA (Gatch et al., 2009) . MDAI seems to have behavioral effects similar to those of MDMA as it substituted for the discriminative stimulus effects of MDMA, but not of LSD (Nichols et al., 1990) . However, it is not known whether MDAI produces psychostimulant-like effects similar to MDMA. This is of more than academic interest as there is evidence that MDAI has been advertised as a legal alternative to the controlled cathinone mephedrone and that capsules and tablets sold as MDAI often contain cathinone compounds (Gallagher et al., 2012) . Correspondingly, MDAI has been found in samples of 'bath salts' or in blood samples of users increasingly over the past 4 years (Marinetti and Antonides, 2013; Elliott and Evans, 2014; Uralets et al., 2014) . However, there is little evidence whether MDAI also produces psychostimulant-like effects similar to other compounds regularly included in 'bath salts.' MDAI failed to substitute for the discriminative stimulus effects of amphetamine, producing maximal effects of 50% drugappropriate responding with considerable suppression or responding (Johnson et al., 1991b) , but MDMA also produces inconsistent effects in amphetamine-trained subjects as mentioned previously.
The aim of the present study was to test the potential abuse liability of MDAI and to assess the degree of similarity between the behavioral effects of MDAI and MDMA. The two questions are not entirely independent as possessing highly similar pharmacological mechanisms and behavioral effects can imply similar patterns of recreational use. Behavioral studies of the abuse liability of potential psychostimulants include locomotor activity, discriminative stimulus effects similar to controlled substances such as cocaine or methamphetamine, conditioned place preference, and finally, the ability to maintain drug-seeking behavior in a self-administration test. In the present study, the ability of MDAI to alter locomotor activity in mice was tested. Because MDMA produces both psychostimulant and hallucinogen-like discriminative stimulus effects, the ability of MDAI to substitute in rats trained to discriminate MDMA, methamphetamine, cocaine, and DOM was also tested. Finally, to test for reward effects, the ability of MDAI to produce conditioned place preference was tested.
Methods

Subjects
Male Swiss-Webster mice were obtained from Harlan (Indianapolis, Indiana, USA) at ∼ 8 weeks of age and tested at ∼ 10 weeks of age. Mice were group housed in cages on a 12 : 12 h light/dark cycle and were allowed free access to food and water. Male Sprague-Dawley rats were obtained from Harlan. All rats were housed individually and were maintained on a 12 : 12 light/dark cycle (lights on at 07 : 00 h). Body weights were maintained at 320-350 g by limiting food to 15 g/day, which included the food received during operant sessions. Water was readily available. All housing and procedures were in accordance with Guidelines for the Care and Use of Laboratory Animals (National Research Council, 2011) and were approved by the University of North Texas Health Science Center Animal Care and Use Committee.
Locomotor activity
The study was carried out using 40 Digiscan (model RXYZCM; Omnitech Electronics Inc., Columbus, Ohio, USA) locomotor activity testing chambers (40.5 × 40.5 × 30.5 cm) housed in sets of two within sound-attenuating chambers. A panel of infrared beams (16 beams) and corresponding photodetectors were located in the horizontal direction along the sides of each activity chamber. A 7.5 W incandescent light above each chamber provided dim illumination and fans provided an 80-dB ambient noise level within the chamber.
Separate groups of eight mice were injected with either vehicle (0.9% saline), MDMA (0.1, 0.25, 0.5, 1 mg/kg), or MDAI (1, 3, 10, or 30 mg/kg) immediately before locomotor activity testing. In all studies, horizontal activity (interruption of photocell beams) was measured for 8 h within 10 min periods, beginning at 08 : 00 h (1 h after lights on).
Discrimination procedures
Standard
behavior-testing chambers (Coulbourn Instruments, Allentown, Pennsylvania, USA) were connected to IBM-PC compatible computers through LVB interfaces (Med Associates, East Fairfield, Vermont, USA). The computers were programmed in Med-PC for Windows, version IV (Med Associates), for the operation of the chambers and collection of data.
Using a two-lever choice methodology, a pool of rats previously trained to discriminate either MDMA (1.5 mg/kg), DOM (0.5 mg/kg), methamphetamine (1 mg/kg), or cocaine (10 mg/kg) from saline, as described previously (Gatch et al., 2009) , were tested. Rats received an injection of either saline or drug and were subsequently placed in the behavior-testing chambers, where food (45 mg food pellets; Bio-Serve, Frenchtown, New Jersey, USA) was available as a reinforcer for every 10 responses on a designated injection-appropriate lever. The pretreatment time was 10 min for cocaine and methamphetamine, 15 min for MDMA, and 30 min for DOM. Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. The rats received ∼ 60 of these sessions before they were used in tests for substitution of the experimental compounds. Rats were used in testing once they had achieved nine of 10 sessions at 85% injection-appropriate responding for both the first reinforcer and the total session. The training sessions occurred on separate days in a double alternating manner (drug-drug-saline-saline-drug, etc.) until the training phase was complete, after which substitution tests were introduced into the training schedule such that at least one saline and one drug session occurred between each test (drug-saline-test-saline-drug-test-drug, etc.). The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two previous training sessions.
Test sessions lasted for a maximum of 20 min. In contrast with training sessions, both levers were active, such that 10 consecutive responses on either lever led to reinforcement. Data were collected until the first reinforcer was obtained or for a maximum of 20 min. Each compound was tested in groups of six rats. For dose-effect experiments, intraperitoneal injections (1 ml/kg) of saline or MDAI (0.5, 1, 2.5, 5, and 7.5 mg/kg) were administered 60 min before the start of the session. For the time-course experiments, the lowest dose that fully substituted without significant rate effects in the dose-effect studies was selected. The rats were injected with MDAI and placed in the test chambers 5, 15, 30, 60, 120, and 240 min after administration. A repeated-measures design was used, such that each rat was tested at all doses or all time points of a given drug.
Conditioned place preference
The place preference apparatus consisted of 16 acrylic test chambers (12 × 6 × 12-inch, lwh) (Model 71-CFCPP; Omnitech Electronics Inc.) with interchangeable grid (bar) and hole (perforated) floors (full, 12 × 6-inch, and split, 6 × 6-inch). The position of the mouse within the apparatus was recorded using a photocell-based system (Model 71-CPPX; Omnitech Electronics Inc.). The acrylic chambers were housed separately in soundattenuating chambers (Model 71-ECC; Omnitech Electronics Inc.). Ambient noise within the chambers was 64 dB and testing took place under dim illumination (31.8 1.5 lux).
Place conditioning, using a biased-assignment model, consisted of three phases: a pretest for initial floor bias, four place conditioning sessions, and a final preference test. The pretest was performed on day 1, during which initial floor bias was examined by injecting mice intraperitoneally with 0.9% saline and then allowing them free access to both floor types for 30 min. The amount of time spent on either floor was measured and the floor on which less time was spent was designated the drug-paired floor. Positioning of the floors alternated between chambers. On days 2 and 3, place conditioning occurred, wherein mice received one vehicle and one drug conditioning session on both days. In the mornings, mice were injected with saline or MDAI (0.1, 0.3, 1, 3, or 10 mg/kg) and placed in the chamber with the drugpaired floor for 30 min, and then returned to their home cage. After 4 h, mice were injected with saline and immediately placed in the chambers with the non-drugpaired floors for 30 min. The final preference test, occurring on day 4, was identical to the pretest. All subjects were administered 0.9% saline and the time spent on the drug-paired floor was measured. Sixteen mice were tested at each dose.
Drugs
(− )-Cocaine hydrochloride, (+ )-methamphetamine hydrochloride, MDMA, DOM, and MDAI were provided by the National Institute on Drug Abuse Drug Supply Program. All drugs were dissolved in 0.9% saline and were administered intraperitoneally in a volume of 1 ml/kg in rats and 10 ml/kg in mice.
Data analysis
Locomotor activity data were expressed as the mean number of photocell counts in the horizontal plane (ambulation counts) during each 10 min period of testing. A 30 min period, beginning when maximal stimulation of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data. A two-way repeated-measures analysis of variance was carried out on horizontal activity counts/10 min interval. A one-way analysis of variance was carried out on horizontal activity counts for the 30 min period of maximal effect, and planned comparisons were performed for each dose against saline control using single degree-of-freedom F tests.
Drug-discrimination data are expressed as the mean percentage of drug-appropriate responses occurring in each test period. Rates of responding were expressed as a function of the number of responses made divided by the total session time. Graphs for percent drug-appropriate responding and response rate were plotted as a function of the dose of the test compound (log scale). Percent drug-appropriate responding was shown only if at least three rats completed the first fixed ratio. Full substitution was defined as more than 80% drug-appropriate responding and not statistically different from the training drug.
The potencies (and 95% confidence intervals) of MDAI in MDMA-trained, DOM-trained, cocaine-trained, and methamphetamine-trained rats were calculated by fitting straight lines to the linear portion of the dose-response data for each compound by means of OriginGraph (OriginLab Corporation, Northampton, Massachusetts, USA). Rates of responding were expressed as a function Effects of MDAI in rodents Gatch et al. 499 of the number of responses made divided by the total session time. Response rate data were analyzed by oneway repeated-measures analysis of variance. Effects of individual doses were compared with the vehicle control value using a-priori contrasts.
Conditioned place preference data were expressed as the mean time in seconds spent on the drug-paired floor over 30 min. Preference scores were calculated by subtracting the pretest time on the drug-paired floor from the posttime on the drug-paired floor. The data were analyzed using a one-way analysis of variance of preference scores over dose. Effects of individual doses were compared with the vehicle control value using a-priori contrasts. The criterion for significance was set a priori at P less than 0.05. Because the depressant effects seemed to be decreasing at 30 mg/kg and because of the appearance of stimulant effects, 100 mg/kg was also tested. Data are not shown because lethality occurred in eight of eight mice following 100 mg/kg MDAI.
Results
Locomotor activity
Drug discrimination Dose effect
MDAI fully substituted for the discriminative stimulus effects of MDMA (ED 50 = 1.07 mg/kg, 95% confidence interval 0.27-4.28 mg/kg), with peak effects (100%) following 2.5 mg/kg MDAI (Fig. 2) . MDAI fully substituted in cocaine-trained rats (ED 50 = 3.66 mg/kg, 0.86-15.26 mg/kg), with a peak of 81 11% following 7.5 mg/kg. MDAI also fully substituted in DOM-trained rats (ED 50 = 2.62 mg/kg, 0.49-14.09 mg/kg), with a peak of 80 20% at 5 mg/kg; however, when tested at 7.5 mg/kg, drug-appropriate responding decreased to 69 19%. MDAI produced a peak of only 73 24% drug-appropriate responding in methamphetamine-trained rats following 7.5 mg/kg (Fig. 2) . A methamphetamine-trained rat tested following the administration of 10 mg/kg evidenced tremors; thus, 7.5 mg/kg was used as the maximum dose in all subsequent testing. MDAI (5 and 7.5 mg/kg) decreased the rate in cocaine-trained rats [F(4,20) = 46.67, P < 0.001], methamphetamine-trained rats [F(4,25) = 12.07, P < 0.001], and DOM-trained rats [F(4,20) = 6.98, P < 0.001]. MDAI (tested at doses from 0.3 to 3 mg/kg) did not alter the response rate in MDMA-trained rats [F(4,20) = 1.31, P = 0.302].
Time course
Doses of MDAI that produced peak effects without considerable rate effects were selected for use in the time-course studies (Fig. 3) . MDAI (2.5 mg/kg) produced 100% MDMA-appropriate responding within 5 min that lasted 30 min. MDMA-appropriate responding was still above 80% at 60 min and then decreased to 49 22% at 120 min and then to 15% at 240 min. The response rate was suppressed at 5 and 15 min following administration [F(6,30) = 3.49, P < 0.01]. In DOM-trained rats, MDAI (5 mg/kg) suppressed responding at 5 and 30 min. At 15 min, 24 24% DOM-appropriate responding was observed. Responding peaked at the 60 min time point (90.5 9.5%) and then decreased to 82 16% at 120 min, and 15 15% at 240 min after the administration of MDAI. Response rate was suppressed from 5 to 30 min following administration [F(6,30) = 4.94, P < 0.001]. None of the six rats responded at 5 min following administration, three of six rats responded at 15 min, and two of six rats responded at 30 min.
In cocaine-trained rats, MDAI (5 mg/kg) suppressed responding until the 60 min time point in cocaine-trained rats. Peak cocaine-appropriate responding (97 3%) occurred at 60 min, decreased to 78 14% at 120 min, and then to 2 2% at 240 min after the administration of MDAI. The response rate was suppressed from 5 to 60 min following administration of MDAI [F(6,30) = 20.02, P < 0.001]. A time course of 5 mg/kg MDAI in methamphetamine-trained rats showed maximal effects of 64% methamphetamine-appropriate responding at 60 min following administration (Fig. 3) . Low levels of methamphetamine-appropriate responding (31-32%) were observed at 5 and 120 min and the effects of MDAI had decreased to 11% at 240 min after administration. Responding was suppressed at 15 and 30 min [F(6,30) = 6.59, P < 0.001]. Effects of MDAI in rodents Gatch et al. 501 Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
Conditioned place preference MDAI (0.1 to 10 mg/kg) was tested for its ability to produce a conditioned place preference (Fig. 4) . There was a significant overall effect of dose [F(5,90) = 2.86, P < 0.02]. MDAI produced significant levels of CPP following administration of 0.3 to 10 mg/kg, whereas vehicle (saline) and 0.1 mg/kg MDAI produced effects no different from baseline. Higher doses were not tested because of the apparent plateau of effect and because of adverse effects observed in mice in the locomotor activity study.
Discussion
Recreational use of MDAI as a substitute for MDMA or for cathinone stimulants has been reported (Marinetti and Antonides, 2013; Elliott and Evans, 2014; Uralets et al., 2014) . However, MDAI is not currently scheduled as a controlled substance (Casale and Hays, 2011) and there is limited research on its behavioral effects in laboratory models of substance abuse. In the present study, MDAI produced locomotor and discriminative stimulus effects similar to those produced by MDMA, and produced conditioned place preference, as does MDMA (Bilsky et al., 1990; Daza-Losada et al., 2009; Roger-Sánchez et al., 2013) . MDAI produced lethality in all mice tested at 100 mg/kg. The LD 50 of MDMA is 97 mg/kg (intraperitoneal) in mice (Hardman et al., 1973) ; thus, MDMA may be somewhat less potent at producing lethal effects than MDA. Taken together, these findings suggest that MDAI may have liability for abuse comparable with that of MDMA.
MDAI depressed locomotor activity within the first 30 min of administration, although a stimulant effect was observed 1 to 3 h following administration of the highest dose (30 mg/kg). These effects may seem curious as MDMA (which is structurally and pharmacologically similar to MDAI) produces a stimulation of locomotor activity (Gold et al., 1989; Callaway et al., 1990) . However, a broader assessment of the time-course and dose-effect of MDMA uncovered effects very similar to those of MDAI. In the present study, both compounds produced rapid-onset locomotor depression at lower doses and slower onset, long-lasting locomotor stimulation at higher doses. In addition, the cathinone flephedrone (Gatch et al., 2013) , the sympathomimetic dimethylamylamine (Dolan and Gatch, 2015) , and the phenethylamine hallucinogens 2C-D and DOC (Eshleman et al., 2014) produced a profile similar to that of MDAI and MDMA: depressant effects, followed by rebound stimulant effects. In contrast, a wide range of psychostimulants produce locomotor stimulation, often in an-inverted U-shaped function, such that increasing doses produce increases in locomotor activity, with the highest doses producing marked decreases in locomotor activity (Katz et al., 2001; Carroll et al., 2009; Gatch et al., 2013; 2015a; 2015b) . When tested in the same manner, most hallucinogens produce dose-dependent depression of locomotor activity (Gatch et al., 2011; Eshleman et al., 2014) . It is not clear why a pharmacologically diverse group of compounds would all produce this unusual biphasic effect.
MDAI fully substituted for the discriminative-stimulus effects of MDMA (100%). MDAI also fully substituted for cocaine and DOM in both the dose-effect and the time-course studies, but at doses higher than those required to substitute for MDMA and that produced substantial suppression of the response rate. However, MDAI produced less than 80% drug-appropriate responding in methamphetamine-trained rats in both the dose-effect and time-course studies, also at doses that considerably suppressed rate of responding. Despite the differences in doses at which MDAI substituted, there were no statistically significant differences in ED 50 values, as evidenced by completely overlapping 95% confidence intervals. However, a qualitative difference in the effects of MDAI between the training compounds was apparent in the time-course study. Full substitution with little rate suppression was observed in the MDMAtrained rats during the time interval of 5 to 30 min, whereas considerable rate suppression was observed in the DOM-trained, methamphetamine-trained, and cocaine-trained rats, with only modest drug-appropriate responding during the same time period. Full substitution took 60 min to appear in the DOM-trained and cocaine-trained rats. The differences in suppression of the response rate can be attributed to the different doses tested (2.5 mg/kg in MDMA-trained rats, and 5 mg/kg in the cocaine-trained, methamphetamine-trained, and DOM-trained rats). However, the difference in onset of the discriminative stimulus effects is striking. Why MDAI should substitute for MDMA at earlier time points than for cocaine, methamphetamine, and DOM is not clear.
These findings are in agreement with earlier work that MDAI substituted for the discriminative stimulus effects of MDMA (Nichols et al., 1990) and partially substituted (50%) for the discriminative stimulus effects of amphetamine at a dose that produced marked rate suppression (Johnson et al., 1991b) . However, the finding in the present study that MDAI substituted for the discriminative stimulus effects of DOM does not appear to be in agreement with the finding that MDMA did not substitute in rats trained to discriminate LSD (Nichols et al., 1990) . A reason for the apparent discrepancy is that in the earlier study, MDAI was tested 30 min following administration in the LSD-trained rats. In the present study, MDAI produced no DOM-appropriate responding 30 min after administration in agreement with the earlier study, and full substitution was not observed until the 60 min time point. This suggests that MDAI does produce hallucinogen-like effects, but at times later than those tested in the earlier study.
Like MDAI, MDMA also fully substituted for the discriminative-stimulus effects of DOM (Schechter 1998; Gatch et al., 2009 ). However, unlike MDAI, MDMA fully substituted in methamphetamine-trained rats (Gatch et al., 2009 ), but did not substitute in cocaine-trained or amphetamine-trained rats (Oberlender and Nichols 1988; Khorana et al. 2004) , although one study reported partial substitution in cocaine-trained rats (Kueh and Baker, 2007) . The drug-discrimination data presented here are in general accordance with the mechanistic data presented previously for MDAI (Johnson et al., 1991a; Simmler et al., 2014b) . Of the training drugs utilized, the pharmacological profile of MDAI is most similar to that of MDMA, showing the relative affinities of NET > SERT > DAT, with MDAI producing affinities of 0.65, 8.3, and 31 µmol/l (respectively) and MDMA producing affinities of 0.45, 1.36, and 17 µmol/l for the three transporters (Simmler et al., 2014a; 2014b) .
This explains the potent substitution by MDAI for the discriminative stimulus effects of MDMA and, to a lesser extent, DOM, a 5-HT2 partial agonist (Sanders-Bush et al., 1988) . Furthermore, these data suggest a complex discriminative stimulus profile for MDAI, similar to that of MDMA, which is mediated by both serotonin and dopamine (Goodwin and Baker, 2000; Goodwin et al., 2003) . It has been reported previously that MDMA adopts a more stimulant-like discriminative stimulus profile at higher doses that is mediated by dopaminergic signaling (Gatch et al., 2009; Harper et al., 2014) . The data from the current study indicate similar effects with higher doses of MDAI (5-7.5 mg/kg) in cocaine-trained and methamphetamine-trained rats, the effects of which are primarily mediated by dopamine (Callahan et al., 1990; Kleven et al., 1990; Tidey and Bergman, 1998) .
MDAI produced conditioned place preference at doses from 0.3 to 10 mg/kg, which provides evidence that MDAI produces reward-like effects and may maintain self-administration. These findings are comparable with earlier reports that MDMA produces conditioned place preference (Bilsky et al., 1990; Daza-Losada et al., 2009; Roger-Sánchez et al., 2013) and are not surprising, given that MDAI is being used on the street as a substitute for MDMA (Sainsbury et al., 2011; Corkery et al., 2013) or mephedrone (Gallagher et al., 2012) .
Conclusion
MDAI produced locomotor, discriminative stimulus, rewarding, and lethal effects similar to those of MDMA. MDAI, like MDMA, produced locomotor, discriminative stimulus, and rewarding effects not only like those of psychostimulants but also produced locomotor and discriminative stimulus effects like those of hallucinogens. These data suggest that MDAI has an abuse liability similar to that of MDMA, and is agreement with reports that MDAI is increasingly being used as a substitute for MDMA on the street.
